Affimed N.V.

welcome to AFIMET's third quarter 2024 earnings and corporate update call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you'll need to press star 11 on your telephone. You will then hear an automated message advising that your hand is raised. If you would like to remove yourself from the queue, please press star 11 again. As a reminder, today's conference call is being recorded. I would now like to introduce you to your host for today's call, Alistair Petas, Head of Investor Relations at AfriMed. Please go ahead.

Thank you, Lisa, and thank you all for joining us today for our third quarter 2024 business and financial update call. Before we begin, I'd like to remind everyone that we posted the relevant press release and presentation we'll be using today on the investor relations section of our website. On the call today, we have our Members of our management team, including Sean Leland, our Chief Executive Officer, Andreas Harstrick, our Chief Medical Officer, Wolfgang Fischer, our Chief Operating Officer, Denise Mueller, our Chief Business Officer, and Harry Welton, our Consulting Chief Financial Officer. Our financials today will be presented by our VP of Finance, Michael Wolff. The team will be available for Q&A after the prepared remarks. Before we start, I'd like to remind you that today's presentation contains projections and forward-looking statements regarding future events. These statements represent our beliefs and assumptions only as of the date of this call. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements. even if new information becomes available in the future. These forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in these statements due to various factors, including but not limited to those identified under the section entitled Risk Factors in Our Filings with the SEC and those identified under the section entitled Forward-Looking Statements in the Press Release that we issued today and filed with the SEC. With that, I'll turn the call over to Sean. Sean? Thank you, everyone.

Thank you for joining us today. I've been with the company for a couple of months now, and during this time, I've had the chance to immerse myself in the incredible work that is being done at AFIMED. I am genuinely impressed by both the groundbreaking science and the clinical milestones our team has achieved over the last 12 months. The depth of expertise within our organization and the potential of our platform are truly remarkable, and they have only deepened my confidence in the work that is being done at the company. The main reason I decided to join AFIMED was the data demonstrating clinical proof of concept across three different assets spanning solid tumors and hematologic malignancies. Our therapies have shown activity in both monotherapy and combination studies. all of our innate cell engagers are moving well beyond clinical proof of concept, which is having an impact on how we shape and focus the company for the future. Affymed's innovation is bringing meaningful benefits to patients who have often exhausted all other therapeutic options and indications where there are significant unmet medical needs. In addition to the promising activities shown with our innate cell engagers, both as model therapy and in combination, They have also demonstrated a favorable and differentiated safety profile, even in these challenging and heavily pretreated patient populations, many of whom are in the end stage of their disease. The fact that we continue to observe meaningful and often durable responses gives us immense confidence. These results are what excite me the most about our platform and therapies, which offer hope where little has existed before. I'd like to highlight the differentiated safety profile of our NK cell engagers, which enables us to target molecules with the narrow therapeutic index due to their tumor specificity. NK cells naturally distinguish between tumor and healthy tissue. So when targeting CD123, for instance, our engager binds to normal tissue, but does not trigger NK cell killing due to inhibitory factors in healthy cells. This leads to a safer profile and improved therapeutic index for our CD123 engager, AFM28, compared to TCEs, ADCs, and CAR-T, which have toxicities that are often unmanageable and sometimes fatal. Although we observe some toxicity with AFM28, these events are fewer and manageable. This tumor specificity is also seen with AFM24, our EGFR engager, which avoids the scan of mucosal toxicities associated with other EGFR targeting approaches further underscores the unique safety advantages of our NK cell engagers. Today's call will be brief as our key clinical updates will be shared in December. At the upcoming ASH 2024 conference, we are excited to have an oral presentation on AFM28 as well as preclinical data at a poster session. Data from our Luminize 203 trial will also be presented at a poster session. Clearly, this recognition is based on the strength of our data. This is not only exciting, it is validating that our innate cell engagers may have a key role in the future paradigm. On December 17th, we will host a company conference call to provide a clinical update on AFM24. I'd like to take a moment now to reflect on what we have been doing since we last spoke. Since joining, I've hit the ground running, speaking with members of the financial community, potential partners, KOLs, and many of our clinical investigators to gain their perspectives on the value they see in our therapies and how they would like to see us continue their development. I am taking this feedback very seriously and use it to further refine our strategy and our focus. We will maintain our focus on clinical development priorities. Our decisions about our programs will be based on clinical benchmarks, the competitive landscape, and the commercial potential. Our goal going forward will be to deliver therapies that not only demonstrate strong clinical efficacy, but also have a meaningful impact on the treatment paradigm and are commercially sustainable. In addition, we understand that partnerships will play a pivotal role in accelerating our progress. Drawing on my extensive background in business development, we are pursuing a wider range of potential collaborations. Broadening our thinking on the types of collaborations will allow us to engage with a more diverse set of potential partners and further expand our strategic options. AFIMA today is a more streamlined and focused organization. As we take our company into the future, I'm committed to delivering differentiated clinical data from our ongoing trials and ensuring steady, measurable progress across our programs. I reiterate my commitment to improving the financial health of our company, and we are actively working on improving our financial position. My number one objective is to ensure that our company is well capitalized to deliver on the expectations we have heard from the financial community and our investigators in order for us to continue to further the clinical development of our programs and ensure the long-term success of our company. This will enable us to evolve the company such that we not only develop innovative therapies, but we operate in a way that maximizes value for all stakeholders. That includes our investors, our partners, and most importantly, the patients who depend upon us. With that, I'll pass the call to Andreas to give you an update on our clinical trial progress.